Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

(Reuters) -The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory-robbing disease.

These are some of the areas where Eli Lilly, flush with cash from its GLP ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory ...

At a time when global coordination against health threats is critical, recent policy shifts in the U.S. have created a ...

Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals ... The collaboration agreement centres around Alchemab’s antibody discovery platform, which uses patient samples from those with ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...